MARIA FUNAIR: Open Payments
NPI 1710175948 · PITTSBURGH, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,013 in 167 payments from 31 companies in 2025. Trend: 2023 $2,902 · 2024 $3,113 · 2025 $3,013
Food & beverage: $2,992Education: $20
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 40 | $571 |
| Novo Nordisk Inc | 25 | $390 |
| AstraZeneca Pharmaceuticals LP | 12 | $334 |
| PFIZER INC. | 18 | $205 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $199 |
| Janssen Pharmaceuticals, Inc | 4 | $159 |
| GlaxoSmithKline, LLC. | 9 | $158 |
| Lilly USA, LLC | 7 | $141 |
| Exact Sciences Corporation | 3 | $71 |
| Abbott Laboratories | 4 | $68 |
Products named: CAPLYTA, QULIPTA, FARXIGA, VRAYLAR, UBRELVY, SPRAVATO, Wegovy, AIRSUPRA.
Industry payments across PA — which companies pay providers there.
